Q2 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript

Aug 5, 2025 / 08:30 PM GMT

Release Date Price: €32.2 (+5.23%)

Transcript 10-Q8-K

Key Points

Positve

Supernus Pharmaceuticals Inc (SUPN) launched Echo, the first subcutaneous apomorphine infusion device for Parkinson's disease, marking a significant product innovation.
The acquisition of Sage Therapeutics is expected to accelerate mid to long-term revenue growth and diversify the revenue base.
Kelvi, a key growth driver, showed strong performance with a 23% increase in prescriptions and a 31% growth in net sales.
Goari prescriptions increased by 14% and net sales by 16%, benefiting from Medicare redesign and improved patient retention rates.
The company has a strong balance sheet with $523 million in cash equivalents and no debt, providing financial flexibility for future growth opportunities.

Negative

Total revenue for Q2 2025 was $165 million, a slight decrease from $168 million in the same quarter last year.
Operating earnings on a GAAP basis decreased to $12 million from $23 million in the same quarter last year, primarily due to higher sales and marketing expenses.
The company expects a full-year 2025 operating loss in the range of $70 million to $80 million, a significant change from previous guidance.
Increased R&D and SG&A expenses are projected due to the inclusion of Sage's operational expenses.
The integration of Sage Therapeutics may present challenges, and the company has not yet disclosed specific future plans for the newly acquired products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SUPN.OQ - Supernus Pharmaceuticals Inc
Q2 2025 Supernus Pharmaceuticals Inc Earnings Call
Aug 05, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Supernas Pharmaceuticals 2nd quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Instruction. Will follow at that time. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your first speaker today, Peter Vozo of ICR Healthcare, investor relations representative for Spurnis Pharmaceuticals. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.